ACADIA Pharmaceuticals Inc represents values of innovation, excellence, and compassion in the pharmaceutical industry. The company's corporate philosophy revolves around developing breakthrough therapies that address unmet medical needs, with a particular focus on neurological and central nervous system disorders. ACADIA Pharmaceuticals Inc aims to improve patients' lives by delivering novel treatments and advancing scientific understanding. With a commitment to rigorous research, collaboration, and patient-centricity, the company strives to make a meaningful impact in healthcare. ACADIA Pharmaceuticals Inc embraces a culture of continuous learning, growth, and ethical practices to drive positive change and bring hope to those in need.

ACADIA Pharmaceuticals Inc is primarily present in the United States.

ACADIA Pharmaceuticals Inc has achieved several significant milestones. The company's groundbreaking drug, pimavanserin, received FDA approval in 2016 for the treatment of Parkinson's disease psychosis (PDP). This made ACADIA the first and only pharmaceutical company with an FDA-approved treatment for this condition. In 2020, ACADIA also received FDA approval for pimavanserin as a treatment for hallucinations and delusions associated with dementia-related psychosis (DRP). These approvals have not only established ACADIA as a leader in the field of neurological therapeutics but also provided hope and improved quality of life for patients suffering from debilitating psychotic symptoms.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative medicines to address unmet medical needs. Founded in 1997, ACADIA has been dedicated to advancing breakthrough therapies for central nervous system disorders. The company focuses on researching and developing small molecule drugs that target specific neurotransmitter receptors in the brain. ACADIA is recognized for its leading drug, Nuplazid, which is approved for the treatment of Parkinson's disease psychosis. Committed to improving patients' lives, ACADIA strives to drive scientific advancements and create value for healthcare providers and stakeholders in the pharmaceutical industry.

The main competitors of ACADIA Pharmaceuticals Inc in the market are Biogen Inc., AbbVie Inc., and Johnson & Johnson.

ACADIA Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

The business model of ACADIA Pharmaceuticals Inc revolves around the research, development, and commercialization of innovative therapies for central nervous system disorders. With a focus on neurology and psychiatry, ACADIA develops and markets drugs that aim to improve the lives of patients suffering from neurological and psychiatric conditions such as Parkinson's disease, schizophrenia, and Alzheimer's disease. Through strategic collaborations, clinical trials, and regulatory approvals, ACADIA aims to bring transformative therapies to market, addressing unmet medical needs in the field of central nervous system disorders. ACADIA Pharmaceuticals Inc continuously strives to enhance patient outcomes and maximize shareholder value through its dedicated efforts in drug development and commercialization.

ACADIA Pharmaceuticals hissesinin F/K oranı 32,34.

ACADIA Pharmaceuticals KUV 3,20 dir.

ACADIA Pharmaceuticals için AlleAktien Kalite Skoru 6/10'dur.

beklenen ACADIA Pharmaceuticals cirosu 972,66 Milyon. USD dir.

beklenen ACADIA Pharmaceuticals karı 96,33 Milyon. USD olarak gerçekleşmiştir.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company is headquartered in San Diego, California, USA. ACADIA Pharmaceuticals is divided into two divisions: clinical development and commercial marketing. In clinical development, the company is working on developing new drugs for the treatment of CNS disorders such as Parkinson's disease, Alzheimer's disease, depressive disorders, and schizophrenia. The goal is to help patients reduce their symptoms and improve their quality of life. The commercial division is responsible for bringing to market and distributing the medication developed by ACADIA Pharmaceuticals. In 2020, the company successfully entered the market with the medication Nuplazid, which is used to treat hallucinations and delusions in patients with Parkinson's disease. ACADIA Pharmaceuticals' business model is based on the development of drugs for the treatment of CNS disorders. The company uses a proprietary chemical technology platform that enables the identification and optimization of novel compounds. An important component of ACADIA Pharmaceuticals' business model is its focus on partnerships with other companies and institutions. By collaborating with other pharmaceutical companies, ACADIA Pharmaceuticals can access a wider network of resources and expertise to accelerate the development of new medications and reduce costs. The company also works closely with academic research institutions to advance the research and development of new compounds. In 2020, ACADIA Pharmaceuticals generated approximately $1.1 billion in revenue. The company employs approximately 1,500 people worldwide and has marketed its products in over 20 countries. ACADIA Pharmaceuticals is listed on the NASDAQ stock exchange under the symbol ACAD. In summary, ACADIA Pharmaceuticals' business model is based on the development and commercialization of innovative therapies for CNS disorders. The company utilizes a proprietary technology platform and collaborates closely with other companies and research institutions to accelerate the development of new medications. With a successful market entry of Nuplazid in 2020, ACADIA Pharmaceuticals is on track to achieve its goals and further expand its business model.

ACADIA Pharmaceuticals, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

ACADIA Pharmaceuticals için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

ACADIA Pharmaceuticals şirketinin ISIN kodu US0042251084’dir.

ACADIA Pharmaceuticals 'nin WKN'si 603035 'dir.

ACADIA Pharmaceuticals için Ticker ACAD’dir.

Son 12 ay içerisinde ACADIA Pharmaceuticals, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için ACADIA Pharmaceuticals, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

ACADIA Pharmaceuticals şirketinin mevcut temettü verimi .

ACADIA Pharmaceuticals dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

ACADIA Pharmaceuticals, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

ACADIA Pharmaceuticals, 'Sağlık' sektörüne atanmıştır.

Son ACADIA Pharmaceuticals tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 01.08.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 01.08.2024 olarak gerçekleşti.

2023 yılında ACADIA Pharmaceuticals tarafından 0 USD olarak temettüler dağıtıldı.

ACADIA Pharmaceuticals hisselerinin temettüleri USD olarak dağıtılır.